NEWS

Coulter Partners places Chairman and Non-Executive Director on the Board of Oxford BioTherapeutics

Coulter Partners was delighted to partner with international biotechnology company, Oxford BioTherapeutics, to secure the appointments of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as non-executive director to the Board of Directors. A clinical-stage biotechnology company developing antibody therapeutics for cancer, Oxford BioTherapeutics has a strong oncology specialist management team and board with significant experience in developing immuno-oncology and antibody-based therapies. The company is based in Oxford, UK, and San Jose, CA.

Bernd Seizinger brings over 20 years of industry experience, from a number of senior executive board positions in pharma and biotech companies on both sides of the Atlantic. These include Bristol-Myers Squibb (VP Oncology Drug Discovery and VP Corporate and Academic Alliances), GPC Biotech (CEO and President), and Chairman of Aprea, Opsona and CryptoMedix.

Jean-Pierre Bizzari brings 32 years’ experience including as EVP and Group Head of Clinical Oncology at Celgene until 2015, and Sanofi Aventis prior to that, and has directed the clinical development and approval of a number of important anti-cancer medicines.

Oxford BioTherapeutics’ chief executive officer, Christian Rohlff, PhD comments, ” We are honored to be welcoming Bernd Seizinger as Chairman, and Jean-Pierre Bizzari as a non-executive director and I thank the exceptional team at Coulter Partners for conducting these searches on our behalf. These appointments of world-renowned experts will support Oxford BioTherapeutics’ transition into a clinical-stage oncology therapeutics development company, with a mature, well-funded clinical ADC/C pipeline and a disruptive early second generation I-O pipeline.”

Speaking about his appointment Dr Seizinger said, “Oxford BioTherapeutics has considerable momentum, progressing an exciting immuno-oncology and ADC pipeline, as well as our fully-funded partnered pipeline. Our corporate evolution is now driven by our broad-scale ability to discover and translate novel targets into biologics drug candidates with compelling in vivo anti-tumor activity.

Jean-Pierre Bizzari added, “I am excited to be joining Oxford BioTherapeutics at this pivotal moment. I believe the Company’s broad pipeline of next generation immuno-oncology candidates against novel checkpoint targets has significant potential to produce transformative medicines“.

For further information please visit: http://www.oxfordbiotherapeutics.com/